바이오센서 시장 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별(2026-2034년)

The global biosensors market size reached USD 33.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 58.9 Billion by 2034, exhibiting a growth rate (CAGR) of 6.42% during 2026-2034. North America leads the market attributed to robust healthcare infrastructure, strong investment in research operations, high demand for personalized medicine, and the presence of leading biosensor manufacturers and tech companies. Technological advancements, rising prevalence of chronic diseases, increasing demand for point-of-care testing (POCT), the expanding applications in healthcare, food, and environmental monitoring, government initiatives, investments in research and development (R&D), emergence of wearable biosensors, and the growing focus on precision medicine and personalized treatment approaches are some of the factors favoring the market growth.

MARKET SIZE & FORECASTS:

• Biosensors market was valued at USD 33.1 Billion in 2025.
• The market is projected to reach USD 58.9 Billion by 2034, at a CAGR of 6.42% from 2026-2034.

DOMINANT SEGMENTS:

• Product: Non-wearable biosensors hold the biggest market share due to their widespread use in clinical diagnostics, medical testing, and laboratory applications. They offer high accuracy, versatility, and ease of integration into existing healthcare systems, enabling efficient disease monitoring and real-time diagnostics without requiring constant wear.
• Technology : Electrochemical biosensors account for the largest market share owing to their high sensitivity, low cost, ease of use, and fast response times. They are widely used in various applications like glucose monitoring and environmental testing because of their reliable performance, portability, and ability to detect a wide range of analytes.
• Application : Blood glucose testing represents the largest segment because of the growing prevalence of diabetes worldwide. With the need for continuous glucose monitoring, electrochemical biosensors offer a cost-effective and efficient solution. This device provides real-time, accurate measurements, helping individuals manage their condition and avoid complications.
• End Use : Point of care testing dominates the market attributed to its convenience, speed, and ability to provide immediate results at the site of patient care. It reduces the need for laboratory visits, enables faster diagnosis, improves patient outcomes, and is especially beneficial in emergency situations and remote areas.
• Region: North America dominates the market accredited to robust healthcare infrastructure, growing demand for innovative medical devices, significant investments in research operations, and the presence of leading biosensor manufacturers. Additionally, favorable reimbursement policies and a large aging population further support the market dominance of the region.

KEY PLAYERS:

• The leading companies in biosensors market include Abbott Laboratories, AgaMatrix Inc. (WaveForm Technologies Inc), DuPont de Nemours Inc., F. Hoffmann-La Roche AG, General Electric Company, LifeScan Inc. (Platinum Equity LLC), Medtronic PLC, Nova Biomedical Corporation, PHC Holdings Corporation, Siemens AG, and Thermo Fisher Scientific Inc.

KEY DRIVERS OF MARKET GROWTH:

• Growing Prevalence of Chronic Illnesses: The rising prevalence of chronic illnesses is driving the biosensors market as continuous monitoring becomes essential for symptom management and early detection. Biosensors enable real-time tracking of critical health parameters, improving the quality of life and preventing complications in patients with chronic conditions.
• Bioprocess Monitoring Advancements: Improvements in bioprocess monitoring, particularly in biotechnology and pharmaceuticals, is propelling the market growth. Real-time monitoring of bioreactor processes improves the accuracy and effectiveness of cell culture, fermentation, and biotechnological applications. Advanced biosensors enable the detection of low molecule concentrations, optimizing production and bioprocess management.
• Improvements in Technology: Technological advancements, such as self-illuminating biosensors and quantum inelastic electron tunneling, are enhancing biosensors' ability to detect biomolecules at extremely low concentrations. These innovations enable label-free, real-time diagnostics, improving accuracy and expanding biosensors' applications in healthcare, environmental monitoring, and on-site diagnostics.
• Growth of Wearable Health Devices: The growing adoption of wearable devices equipped with advanced biosensors is positively influencing the market. These devices enable continuous observation of vital signs like heart rate and glucose levels, offering convenience and real-time health data, especially for individuals with chronic conditions.
• Financial Government Support: Government initiatives and financial support for research and development (R&D) are crucial for driving the growth of the market. These investments aim to improve biosensor functionality, accuracy, and affordability, while public-private collaborations accelerate advancements in personalized medicine, disease monitoring, and diagnostics.
• Awareness about Health and Wellness: Growing public awareness about health and wellness is driving the adoption of biosensor-enabled devices. As individuals become more proactive about their health, there is a rise in the demand for personal health tracking devices to monitor vital signs and identify chronic conditions early, supporting preventive care.

FUTURE OUTLOOK:

• Strong Growth Outlook : The biosensors market is experiencing a strong growth owing to improvements in technology, growing healthcare needs, and rising demand for personalized medicine. Innovations in wearable and non-invasive sensors, along with growing awareness about chronic disease management, are offering a favorable market outlook globally.
• Market Evolution : The biosensors market is evolving with rapid technological advancements, such as miniaturization, integration with mobile health platforms, and improved accuracy. These developments are broadening the range of applications, such as medical diagnostics and environmental monitoring, creating new opportunities for market growth and innovation.

With the aging global population, there is a rise in the demand for dependable and effective healthcare options. Biosensors are essential for disease monitoring, chronic condition management, such as diabetes, and facilitating early diagnosis. As personalized and preventive healthcare gains attention, biosensors are becoming essential for monitoring health in real-time, enhancing patient results. In addition, non-invasive monitoring methods, like those employed in wearable biosensors, are sought after. These devices provide the benefit of ongoing monitoring without requiring invasive methods, enhancing patient comfort and adherence. This trend is especially advantageous for handling chronic illnesses, such as diabetes, enabling patients to track glucose levels without needing to puncture their skin. Apart from this, both governments and private organizations are significantly funding research initiatives in biosensor technologies. Investment in medical technology innovation, particularly in healthcare solutions aimed at enhancing public health outcomes, are resulting in substantial progress in biosensors. This financial assistance fosters the creation of innovative biosensor applications.

BIOSENSORS MARKET TRENDS:

Increasing Prevalence of Chronic Diseases

The rising occurrence of chronic illnesses, like diabetes, heart diseases, and breathing disorders, is contributing to the growth of the biosensors market. Continuous monitoring is essential for managing symptoms, preventing complications, and enhancing patients' quality of life under these conditions. Biosensors offer a practical approach by facilitating instant monitoring of essential health indicators, which aids in the prompt identification of abnormalities. For instance, individuals with diabetes utilize continuous glucose monitors to oversee blood sugar levels and modify insulin amounts. Likewise, people with cardiac issues depend on biosensors to track heart rate and identify irregular rhythms. With the growing prevalence of chronic illnesses worldwide, the need for biosensors that provide continuous health monitoring is escalating. In 2025, Ottai launched its AI-powered wearable biosensor designed for continuous monitoring and management of chronic diseases. The device uses real-time biomarker tracking, voice-activated logging, and AI-driven insights to deliver personalized lifestyle recommendations. It integrates with health apps to offer a scalable, patient-centric care solution.

Advancements in Bioprocess Monitoring

Improvements in bioprocess monitoring are impelling the growth of the market, especially in the biotechnology and pharmaceutical industries. Real-time observation of bioreactor processes is crucial for maintaining the quality, precision, and effectiveness of cell culture, fermentation, and various biotechnological applications. Biosensors with sophisticated features, including identifying extremely low levels of important molecules, are improving the accuracy of bioprocesses. These sensors facilitate the optimization of media formulation and bioprocess management, vital for increasing production in sectors, such as pharmaceuticals, biotechnology, and alternative proteins. In line with this trend, in 2025, The Cultivated B launched AI-driven multi-channel biosensors for real-time monitoring of bioreactor processes, enhancing accuracy and efficiency in cell culture and fermentation. These inline sensors detect ultra-low concentrations of key molecules and use AI to optimize media formulation and bioprocess control. The innovation supports scalable applications across biotech, pharma, and alternative proteins.

Innovation in Biosensor Sensitivity and Miniaturization

Technological progress, including the creation of self-illuminating biosensors and the application of quantum inelastic electron tunneling, is improving the capacity of biosensors to identify biomolecules at remarkably low concentrations, even down to the picogram level. These advancements allow for instantaneous, label-free diagnostics, providing excellent accuracy and quicker outcomes. The capacity to develop highly sensitive, small, and portable devices enhances the possible uses of biosensors, making them applicable across various sectors, such as healthcare and environmental monitoring. With the growing efficiency and versatility of biosensors, their application in point-of-care diagnostics and on-site monitoring is rising, enhancing the integration of biosensor technology in medical and industrial fields. In 2025, scientists at EPFL developed the first self-illuminating biosensor using quantum inelastic electron tunneling, enabling light generation and detection on a single chip without external light sources. This compact, ultra-sensitive device detects biomolecules at picogram levels, ideal for real-time, label-free diagnostics. The innovation promises scalable, handheld biosensors for medical and environmental applications.

BIOSENSORS MARKET GROWTH DRIVER:

Increasing Adoption of Wearable Devices

The growing use of wearable gadgets like smartwatches, fitness trackers, and health-monitoring bands is offering a favorable market outlook. These gadgets, equipped with sophisticated biosensors, allow users to consistently monitor vital signs like heart rate, glucose levels, and oxygen saturation, enhancing their ability to manage health more efficiently. Wearable devices are especially useful for people with chronic illnesses or those prioritizing wellness, providing convenience and immediate health information without the need for regular doctor appointments. The need for tailored health tracking, along with enhancements in wearable tech, such as better battery longevity and sensor precision, is broadening their application. In 2024, Biolinq secured $58 million to enhance its wearable intradermal glucose biosensor, which tracks glucose levels and activity through microsensors placed under the skin. This groundbreaking gadget aimed to streamline metabolic health monitoring, emphasizing the increasing importance of wearables in individualized healthcare.

Government Initiatives and Funding

Government programs and financial support for research and development (R&D) are essential elements propelling the expansion of the biosensors market. Acknowledging the significance of biosensor technologies for healthcare and environmental monitoring, numerous governing bodies are dedicating substantial resources to foster innovation in this area. These investments aim to enhance biosensor functionality, increase precision, and reduce costs, thereby facilitating broader accessibility for various applications. Furthermore, collaborations between the public and private sectors are crucial for advancing biosensors in personalized medicine, disease monitoring, and point-of-care diagnostics. A notable example is Penn State's announcement in October 2024 of a $1.5 million NSF grant aimed at developing AI-designed biosensors for identifying molecules, such as neurotransmitters. Directed by Professor Aida Ebrahimi, the initiative encompassed K-12 STEM outreach, undergraduate research, and partnerships with industry, highlighting the collective endeavor of academia, industry, and government to promote biosensor advancements.

Rising Awareness about Health and Wellness

The growing public awareness about health and wellness is a key factor driving the adoption of biosensor-enabled devices. As individuals take more initiative regarding their health, there is an increase in the need for personal health tracking devices. More people are becoming interested in monitoring essential indicators, like heart rate, glucose levels, and blood pressure, to improve their health and prevent medical problems. This transition towards self-monitoring is especially driven by the need for early identification of chronic illnesses such as diabetes and hypertension. Gadgets such as fitness trackers and smartwatches provide instant health information, offering crucial insights into overall well-being. In line with this trend, in 2024, Abbott launched Lingo, its over-the-counter continuous glucose monitoring (CGM) biosensor in the US, following FDA clearance in June. Built on FreeStyle Libre tech, Lingo offered real-time glucose tracking, health insights, and habit coaching for non-insulin users. With increased awareness of preventive care, the biosensor market continues to grow, enabling individuals to manage their health effectively.

BIOSENSORS INDUSTRY SEGMENTATION:

Breakup by Product:

• Wearable Biosensors
• Non-Wearable Biosensors

The wearable biosensors segment is driven by the increasing demand for continuous health monitoring and personalized medicine. Consumers are increasingly adopting wearable devices such as smartwatches and fitness trackers that incorporate biosensors to monitor vital signs, physical activity, and other health metrics in real-time. Advances in sensor technology, miniaturization, and wireless connectivity have enhanced the functionality and accuracy of wearable biosensors, making them more attractive to users. Additionally, the growing prevalence of chronic diseases and the aging population are fueling the need for remote patient monitoring and early detection of health issues, further boosting the adoption of wearable biosensors. The integration of biosensors with smartphones and other portable devices facilitates seamless data transmission and analysis, providing users and healthcare providers with valuable insights for managing health and wellness.

The non-wearable biosensors segment is driven by the increasing applications in medical diagnostics, environmental monitoring, and food safety. In medical diagnostics, non-wearable biosensors are widely used for detecting various biomarkers, pathogens, and diseases, offering rapid, accurate, and cost-effective solutions for clinical and laboratory settings. Environmental monitoring applications leverage non-wearable biosensors to detect pollutants, toxins, and other harmful substances in air, water, and soil, contributing to public health and safety. In the food industry, non-wearable biosensors are utilized for quality control and safety assurance by detecting contaminants and ensuring compliance with regulatory standards. The rising awareness about the importance of early disease detection, environmental protection, and food safety is driving the demand for non-wearable biosensors.

Breakup by Technology:

• Electrochemical Biosensors
• Optical Biosensors
• Piezoelectric Biosensors
• Thermal Biosensors
• Nanomechanical Biosensors
• Others

The electrochemical biosensors segment is driven by the increasing demand for highly sensitive and selective detection methods in medical diagnostics, environmental monitoring, and food safety. The ability of electrochemical biosensors to provide rapid, accurate, and cost-effective analysis makes them highly desirable across various applications. Advances in nanotechnology and materials science have further enhanced their performance, enabling the development of miniaturized and portable devices. Additionally, the rising prevalence of chronic diseases, such as diabetes, necessitates the widespread use of electrochemical biosensors for continuous glucose monitoring, thereby fueling market growth.

The optical biosensors segment is driven by the increasing need for high-throughput and label-free detection methods in research, clinical diagnostics, and environmental monitoring. Optical biosensors offer exceptional sensitivity and specificity, making them ideal for detecting a wide range of analytes, including biomolecules, pathogens, and pollutants. Advances in photonics and biophotonics have significantly improved the performance of optical biosensors, enabling real-time and multiplexed detection. The growing adoption of point-of-care testing and personalized medicine further boosts the demand for optical biosensors, as they provide rapid and accurate results.

The piezoelectric biosensors segment is driven by the increasing utilization in applications requiring the detection of mechanical changes due to their high sensitivity and rapid response time. These biosensors are particularly effective in detecting mass changes, making them valuable in various fields, including medical diagnostics, environmental monitoring, and industrial processes. The growing demand for portable and non-invasive diagnostic tools is fueling the adoption of piezoelectric biosensors. Furthermore, advancements in piezoelectric materials and microfabrication technologies have enhanced the performance and miniaturization of these sensors, broadening their application scope.

The thermal biosensors segment is driven by the increasing need for highly accurate and reliable temperature-based detection methods in biomedical and industrial applications. Thermal biosensors, which measure changes in temperature as a result of biochemical reactions, offer high sensitivity and specificity. They are widely used in monitoring metabolic activities, detecting pathogens, and assessing food quality. The advancements in microelectromechanical systems (MEMS) and nanotechnology have significantly improved the performance of thermal biosensors, enabling their miniaturization and integration into portable devices.

The nanomechanical biosensors segment is driven by the increasing demand for ultra-sensitive detection methods capable of measuring minute changes at the nanoscale. These biosensors leverage mechanical properties such as mass, stiffness, and surface stress to detect the presence of analytes with high precision. The growing applications in genomics, proteomics, and environmental monitoring are boosting the adoption of nanomechanical biosensors. Advances in nanotechnology and materials science have enabled the development of highly sensitive and miniaturized nanomechanical biosensors, expanding their utility in various fields.

The others segment, which includes emerging biosensor technologies such as magnetic, acoustic, and thermal biosensors, is driven by the increasing need for innovative and versatile detection methods across various industries. These biosensors offer unique advantages, including high sensitivity, specificity, and the ability to detect a wide range of analytes. The growing demand for advanced diagnostic tools, environmental monitoring systems, and food safety solutions is fueling the development and adoption of these biosensors.

Breakup by Application:

• Blood Glucose Testing
• Cholesterol Testing
• Blood Gas Analysis
• Pregnancy Testing
• Drug Discovery
• Infectious Disease Testing
• Others

The glucose testing segment is driven by the increasing prevalence of diabetes worldwide, which necessitates continuous monitoring and management of blood glucose levels. Advances in biosensor technology have led to the development of more accurate, user-friendly, and cost-effective glucose monitoring devices, including continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) systems . These innovations have significantly improved patient compliance and outcomes by enabling real-time glucose tracking and data integration with digital health platforms.

The cholesterol testing segment is driven by the increasing incidence of cardiovascular diseases (CVDs), which are closely linked to high cholesterol levels. Early detection and management of cholesterol are crucial for preventing CVDs, leading to a higher demand for cholesterol testing biosensors. Technological advancements have resulted in more reliable and faster cholesterol testing devices, including portable and point-of-care systems that provide immediate results. Additionally, rising health consciousness, routine health check-ups, and the emphasis on preventive healthcare practices have spurred the adoption of cholesterol testing biosensors.

The blood gas analysis segment is driven by the increasing prevalence of respiratory and metabolic disorders that require precise monitoring of blood gas levels. Conditions such as chronic obstructive pulmonary disease (COPD), asthma, and renal diseases necessitate regular blood gas analysis to manage and adjust treatment plans effectively. Technological advancements have led to the development of portable and point-of-care blood gas analyzers, making it easier for healthcare providers to perform timely and accurate assessments. Furthermore, the growing adoption of these devices in emergency and critical care settings, where rapid decision-making is crucial, significantly contributes to the market's expansion.

The pregnancy testing segment is driven by the increasing demand for home-based and point-of-care diagnostic solutions that offer convenience and privacy. Technological advancements have led to the development of highly sensitive and easy-to-use pregnancy test kits that provide quick and accurate results. The rising awareness about reproductive health and the importance of early pregnancy detection for better prenatal care have also fueled the demand for these testing kits. Additionally, the increasing prevalence of planned pregnancies, coupled with the availability of affordable and accessible testing solutions, further boosts the market.

The drug discovery segment is driven by the increasing need for efficient and cost-effective methods to identify new therapeutic compounds and evaluate their efficacy and safety. Biosensors offer significant advantages in drug discovery by enabling real-time, high-throughput screening of potential drug candidates. Technological advancements have enhanced the sensitivity and specificity of biosensors, making them invaluable tools in the early stages of drug development. Additionally, the growing prevalence of chronic diseases and the demand for personalized medicine have spurred investment in biosensor technologies to accelerate drug discovery processes.

The infectious disease testing segment is driven by the increasing incidence of infectious diseases globally, necessitating rapid and accurate diagnostic solutions. Biosensors offer significant advantages in the early detection and monitoring of infectious agents, enabling timely intervention and containment. Technological advancements have led to the development of highly sensitive and portable biosensors that can detect a wide range of pathogens, including viruses, bacteria, and fungi. The ongoing threat of pandemics and emerging infectious diseases has further highlighted the importance of efficient diagnostic tools, driving investment and innovation in this segment.

The others segment, encompassing various applications such as environmental monitoring, food safety, and bioprocessing, is driven by the increasing need for real-time, accurate, and cost-effective analytical solutions. In environmental monitoring, biosensors are used to detect pollutants and contaminants, ensuring compliance with regulatory standards and safeguarding public health. In food safety, biosensors provide rapid detection of pathogens and toxins, ensuring the quality and safety of food products.

Breakup by End Use:

• Point of Care Testing
• Home Healthcare Diagnostics
• Research Laboratories
• Security and Biodefense
• Others

The point-of-care testing (POCT) segment is driven by the increasing demand for rapid diagnostic results and the need for immediate clinical decision-making. This demand is fueled by the growing prevalence of chronic diseases such as diabetes and cardiovascular conditions, which require continuous monitoring and timely management. Technological advancements in biosensors have made these devices more portable, user-friendly, and capable of delivering accurate results quickly, enhancing their adoption in decentralized settings like clinics, emergency rooms, and even patients' homes. Additionally, the emphasis on reducing healthcare costs and improving patient outcomes has led to a shift towards point-of-care testing, allowing for faster diagnosis and treatment, thus minimizing hospital visits and stays.

The home healthcare diagnostics segment is driven by the increasing preference for convenient and accessible healthcare solutions. With the rise in the aging population and the growing burden of chronic diseases, there is a significant demand for home-based diagnostic tools that enable continuous monitoring and management of health conditions without frequent hospital visits. Advances in biosensor technology have facilitated the development of portable, easy-to-use devices that patients can operate independently, ensuring real-time health monitoring and early detection of potential health issues.

The research laboratories segment is driven by the increasing need for advanced diagnostic and analytical tools in scientific research and development. Biosensors play a crucial role in various research applications, including disease pathology, drug development, environmental monitoring, and biotechnology. The precision, sensitivity, and versatility of biosensors make them indispensable in detecting and quantifying biological molecules and pathogens, facilitating groundbreaking research and innovation. The continuous advancement in biosensor technology, including the integration of nanotechnology and microfluidics, enhances their performance, making them even more valuable in research settings.

The security and biodefense segment is driven by the increasing concerns over bioterrorism, infectious disease outbreaks, and the need for robust public safety measures. Biosensors are critical in this context due to their ability to provide rapid, accurate detection of biological and chemical threats, enabling timely response and mitigation. Governments and defense organizations invest heavily in biosensor technology to enhance national security and safeguard public health. The development of portable and real-time biosensors supports field deployment, making them essential tools for military and homeland security operations.

The others segment is driven by the increasing demand for biosensors in diverse applications beyond traditional healthcare and security uses. This includes industries such as agriculture, food and beverage, environmental monitoring, and industrial processes. In agriculture, biosensors are used for soil and crop health monitoring, ensuring optimal yield and quality. In the food and beverage industry, they are crucial for quality control and safety assurance by detecting contaminants and pathogens. Environmental monitoring applications benefit from biosensors' ability to detect pollutants and toxins in air, water, and soil, contributing to sustainability efforts.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North America regional market is driven by the increasing prevalence of chronic diseases such as diabetes and cardiovascular conditions, which necessitate advanced diagnostic tools. Additionally, the region benefits from robust healthcare infrastructure, significant investments in research and development, and the presence of major biosensor manufacturers. Government initiatives to promote personalized medicine and growing adoption of wearable biosensors for health monitoring further propel market growth. The high awareness and acceptance of new technologies among consumers and healthcare providers also contribute to the expanding biosensors market in North America.

The Europe regional market is driven by the increasing focus on early disease detection and preventive healthcare, supported by substantial government funding and initiatives. The region's strong regulatory framework ensures high standards for biosensor development and application. Additionally, Europe's aging population contributes to a rising demand for advanced diagnostic solutions, while the presence of leading biosensor companies and extensive research activities foster innovation. Growing applications in environmental monitoring and food safety, along with collaboration between academic institutions and industry players, further accelerate market growth in Europe.

The Asia Pacific regional market is driven by the increasing healthcare needs due to a large and rapidly aging population, along with the rising prevalence of chronic diseases. Economic growth and improving healthcare infrastructure in countries like China and India enhance access to advanced diagnostic tools. Governm

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Biosensors Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Wearable Biosensors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-Wearable Biosensors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Electrochemical Biosensors
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Optical Biosensors
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Piezoelectric Biosensors
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Thermal Biosensors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Nanomechanical Biosensors
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Blood Glucose Testing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cholesterol Testing
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Blood Gas Analysis
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Pregnancy Testing
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Drug Discovery
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Infectious Disease Testing
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by End Use

• 9.1 Point of Care Testing
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Home Healthcare Diagnostics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Research Laboratories
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Security and Biodefense
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AgaMatrix Inc. (WaveForm Technologies Inc)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 DuPont de Nemours Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 F. Hoffmann-La Roche AG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 General Electric Company
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 LifeScan Inc. (Platinum Equity LLC)
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Medtronic PLC
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Nova Biomedical Corporation
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 PHC Holdings Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Siemens AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis